Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P10636 (
tau protein
)
5,110
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Acute encephalopathy
with biphasic seizures and late reduced diffusion (AESD) is a recently clinicoradiologically-established encephalopathy syndrome. In the present study, we examined the levels of cerebrospinal fluid (CSF)
tau protein
, a marker of axonal damage, in 11 patients with AESD. CSF tau levels were normal on day 1 and increased from day 3 of the disease between the initial and the secondary seizures. Magnetic resonance imaging (MRI) reveals reduced diffusion in the subcortical white matter during days 3-7. Two patients showed elevated
tau protein
prior to the diffusion abnormality of subcortical white matter on MRI. Levels of CSF neuron specific enolase (NSE), a neuronal marker, were elevated in only two out of seven patients with AESD, and CSF tau levels were also increased in these patients. Our results indicated that
tau protein
is a more sensitive marker than NSE and axonal damage causes the conspicuous MRI findings in AESD patients. A therapeutic strategy for axonal protection should be developed to prevent severe neurological impairment of AESD patients.
...
PMID:The axonal damage marker tau protein in the cerebrospinal fluid is increased in patients with acute encephalopathy with biphasic seizures and late reduced diffusion. 1967 15
Viral infection-associated acute encephalopathy in children is a clinical syndrome with high mortality and neurological sequelae. Its main symptoms of acute phase are impaired consciousness and convulsive status epilepticus with hyperpyrexia.
Acute encephalopathy
with biphasic seizures and late reduced diffusion (AESD) is characterized clinically by biphasic seizures and late MRI abnormalities such as reduced subcortical diffusion. Despite the intensive care, patients with AESD often have severe neurological impairment and it is very difficult to distinguish AESD from febrile seizures in the early phase. Although there is currently no specific biomarker for early diagnosis of acute encephalopathy syndrome, we believe
tau protein
and 8-hydroxy-2'-deoxyguanosine (8-OHdG) are potential biomarkers which could be useful in following the clinical course and monitoring the efficacy of therapies.
...
PMID:[CSF biomarkers in children with acute encephalopathy syndrome]. 2262 18